摘要:
An optical fibre connector includes a connector having a receptacle or socket with a recessed optical fibre ferrule assembly for aligning an optical fibre within the connector. An optical socket has recessed therein a sleeve for receiving and bringing into optical alignment an optical fibre ferrule assembly at an internal end of the socket with a similar optical fibre ferrule assembly of an optical plug connected to the optical socket. The optical connector has a housing with at least two portions that are removably secured to one another. A method of cleaning such a recessed assembley includes removing at least one of said portions from the remainder of the housing. Contamination is then cleaned from the optical fibre ferrule assembly. Then, the the removed portion(s) are reassembled with the remainder of the housing.
摘要:
An optical device has a photodiode placed on a substrate. A guide is formed on the substrate so that it surrounds the photodiode with concentric positioning to an accuracy better than 5 μm. A ferrule of a ferrule assembly engages within the guide for automatic alignment with the photodiode without need for active alignment with monitoring of light signals.
摘要:
A device (1, 7) for separating a sleeve from an implant head, comprising a drive shaft (2) having a proximal end (3) and a distal end (4), the distal end having a cam (6), wherein the cam is disposed such that when, in use, a torque is applied to the drive shaft via the proximal end the cam acts in a direction substantially parallel to the axis of the drive shaft. A method of separating a sleeve from an implant head using such a device.
摘要:
The present invention relates to a method for the deracemisation or chiral inversion of chiral amines by enzymatic treatment. The method employs a stereoselective enzymatic conversion and either a non-selective or partially selective chemical or enzymatic conversion, simultaneously or sequentially. The invention also provides a method for selecting a suitable enzyme, particularly a suitable amine oxidase, and for the generation of novel enzymes suitable for use in the deracemisation method.
摘要:
There is disclosed a medical device adapted to be implanted in the heart of a patient and operable therein i) as a heart valve; or ii) to assist in the functioning of one of the patient's heart valves; or iii) to monitor the functioning of one of the patient's heart valves. The device includes one or more sensors for sensing a physiologically or clinically relevant parameter of a patient. A telemetric communication device telemetrically transmits data related to a parameter sensed by the sensor to a remote device.
摘要:
The present invention relates to a process for the preparation of a compound of the general Formula (I), comprising: a) reacting a compound of the general Formula (II) with a compound of the Formula III R2COOH and a compound of the general Formula IV R3NC under such conditions that compound I is formed, wherein R1 represents a substituted or unsubstituted alkyl, alkenyl, alkynyl, aromatic or non-aromatic, mono-, di- or tricyclic, or heterocyclic structure, and R2 represents a substituted or unsubstituted alkyl, alkenyl, alkynyl, aromatic or non-aromatic, mono-, di- or tricyclic, or heterocyclic structure, and R3 represents a substituted or unsubstituted alkyl, alkenyl, or alkynyl structure. In further aspect the subject invention relates to the use of the obtained products as intermediates for various peptidomimetics, and preferably as a building block in a convergent synthesis of prolyl dipeptide structures.
摘要:
A device (1) for connecting an instrument to a driver, the device comprising: a first connector (3) having at least two protrusions connectable, in use, to the instrument; a mechanism for moving the protrusions between a connected and a disconnected position; and a second connector (17) for connecting the device (1) to the driver, in use. A method of connecting an instrument to a driver.
摘要:
The present invention relates to the use of bisarylsulfonamide compounds of formula I wherein W is a C1-5 branched or unbranched alkyl group or a C2-5 alkenyl group; n is 0 or 1; R1 is H, a C1-8 branched or unbranched alkyl group, a C2-8 alkenyl group, or an aryl or aralkyl group; Ar1 is a substituted thienyl, furyl, pyrrolyl, imidazothiazolyl, thiazolyl, pyridyl or phenyl group; and Ar2 is a substituted phenyl, indolyl or benzoimidazolyl group; in the preparation of a medicament for treating proliferative disorders. Further aspects of the invention relate to compounds of formula I, pharmaceutical compositions thereof, and an assay for determining binding to HDM2.
摘要翻译:本发明涉及式I的双芳基磺酰胺化合物的用途,其中W是C 1-5 - 支链或非支链烷基或C 2-5烯基; n为0或1; R 1是H,支链或非支链烷基,C 2-8链烯基或芳基或芳烷基的C 1-8-18支链或非支链烷基 组; Ar 1是取代的噻吩基,呋喃基,吡咯基,咪唑并噻唑基,噻唑基,吡啶基或苯基; 并且Ar 2是取代的苯基,吲哚基或苯并咪唑基; 在制备用于治疗增殖性疾病的药物中。 本发明的其它方面涉及式I化合物,其药物组合物和用于测定与HDM2结合的测定法。
摘要:
The present invention relates to a process for the preparation of a compound of the general Formula (I), comprising: a) reacting a compound of the general Formula (II) with a compound of the Formula III R2COOH and a compound of the general Formula IV R3NC under such conditions that compound I is formed, wherein R1 represents a substituted or unsubstituted alkyl, alkenyl, alkynyl, aromatic or non-aromatic, mono-, di- or tricyclic, or heterocyclic structure, and R2 represents a substituted or unsubstituted alkyl, alkenyl, alkynyl, aromatic or non-aromatic, mono-, di- or tricyclic, or heterocyclic structure, and R3 represents a substituted or unsubstituted alkyl, alkenyl, or alkynyl structure. In further aspect the subject invention relates to the use of the obtained products as intermediates for various peptidomimetics, and preferably as a building block in a convergent synthesis of prolyl dipeptide structures.
摘要:
The present invention relates to a process for the stereoselective preparation of a compound having the general formula (I) or its respective diastereomers: comprising reacting a compound having the general formula (II) or its diastereomers: with a compound of the general formula III: R3—COOH and a compound of the general formula IV: R4—NC wherein R1 represents each independently, or jointly a substituted or unsubstituted alkyl, alkenyl, alkynyl, aromatic or non-aromatic, mono-, di- or tricyclic, or heterocyclic structure, and R2 represents a hydrogen atom, a substituted or unsubstituted alkyl, alkenyl, alkynyl, aromatic or non-aromatic, mono-, di- or tricyclic, or heterocyclic structure, and R3 represents a substituted or unsubstituted alkyl, alkenyl, or alkynyl, or an aromatic or non-aromatic aromatic or non-aromatic, mono-, di- or tricyclic, or heterocyclic structure. R3—COOH (III) R4—NC (IV)